The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): A new treatment option for invasive bladder cancer patients with lymph node metastasis

Azuma,Haruhito; Inamoto,Teruo; Takahara,Kiyoshi; Nomi,Hayahito; Hirano,Hajime; Ibuki,Naokazu; Uehara,Hiroshi; Komura,Kazumasa; Minami,Koichiro; Uchimoto,Taizo; Saito,Kenkichi; Takai,Tomoaki; Tanda,Naoki; Yamamoto,Kazuhiro; Narumi,Yoshihumi; Kiyama,Satoshi

doi:10.3892/ijo.2014.2378

The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): A new treatment option for invasive bladder cancer patients with lymph node metastasis

Authors:
- Haruhito Azuma
- Teruo Inamoto
- Kiyoshi Takahara
- Hayahito Nomi
- Hajime Hirano
- Naokazu Ibuki
- Hiroshi Uehara
- Kazumasa Komura
- Koichiro Minami
- Taizo Uchimoto
- Kenkichi Saito
- Tomoaki Takai
- Naoki Tanda
- Kazuhiro Yamamoto
- Yoshihumi Narumi
- Satoshi Kiyama
View Affiliations

Affiliations: Department of Urology, Osaka Medical College, Takatsuki City, Osaka 569-8686, Japan, Department of Radiology, Osaka Medical College, Takatsuki City, Osaka 569-8686, Japan
Published online on: April 10, 2014 https://doi.org/10.3892/ijo.2014.2378
Pages: 1895-1903

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have developed a novel bladder preservation therapy for patients with muscle-invasive bladder cancer and lymph node metastasis: balloon-occluded arterial infusion (BOAI) of cisplatin/gemcitabine, with concomitant hemodialysis and irradiation [the so-called ‘OMC (Osaka Medical College) regimen’]. The OMC regimen delivers an extremely high concentration of anticancer agent to the site of the tumor, as well as the pelvic area, without causing any adverse systemic effects. In this study, we investigated the efficiency of the OMC regimen in 34 patients who underwent BOAI with cisplatin (100, 200 or 300 mg) along with 60 Gy of irradiation; patients who failed to achieve CR underwent secondary BOAI with gemcitabine (1,600 mg). The overall clinical response was 73.5% (CR: 35.3%; PR: 17.6%; SD: 20.6%). The 5-year overall and progression-free survival rates were 54.4% and 52.5%, respectively. For treatment failure, N2 stage was selected as a significant risk factor by simple and multiple logistic regression analyses. Cox proportional hazards analyses showed that N2 stage, T4 stage and the presence of hydronephrosis were significant risk factors for overall survival. Indeed, 55.6% of patients with N1 stage achieved a complete response (CR) (vs. 12.5% for N2 patients, p=0.0151), and 90% (9/10) of the CR patients survived without recurrence with an intact bladder after a mean follow-up of 85 (range 7-193) weeks. The 3-year progrssion-free survival rate with an intact bladder was 65.8% (vs. 37.5% for N2, p=0.034), and the 5-year overall survival rate was 71.8% (vs. 30.6% for N2, p=0.004). No patients suffered severe toxicities of Grade II or more; the oldest patient, aged 85 years, successfully completed this therapy. In conclusion, the OMC regimen can be regarded as a new option for patients with macroscopic lymph node involvement, especially those at stage N1. Therapy will improve the feasibility of radical cure even without the need for cystectomy in patients for whom surgery after neoadjuvant chemotherapy would otherwise be necessary, and also facilitate potential cure in patients for whom, otherwise, merely palliative treatment would seem the only option.

View Figures

View References

1.	Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
2.	Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN and Studer UE: Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol. 166:19–23. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Vieweg J, Gschwend JE, Herr HW and Fair WR: The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol. 161:72–76. 1999. View Article : Google Scholar : PubMed/NCBI
4.	Vieweg J, Gschwend JE, Herr HW and Fair WR: Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol. 161:449–454. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Azuma H, Inamoto T, Takahara K, et al: A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen). Int J Oncol. 43:1087–1094. 2013.PubMed/NCBI
6.	Azuma H, Inamoto T, Takahara K, et al: Effect of a novel bladder preservation therapy, BOAI-CDDP–radiation (OMC-regimen). Int J Oncol. 43:79–87. 2013.
7.	Azuma H, Inamoto T, Ibuki N, et al: Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer. Int J Oncol. 38:13–24. 2011.PubMed/NCBI
8.	Azuma H, Inamoto T, Ibuki N, et al: Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Int J Oncol. 37:773–785. 2010. View Article : Google Scholar
9.	Azuma H, Yamamoto K, Inamoto T, et al: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol. 32:592–606. 2009. View Article : Google Scholar
10.	Azuma H, Kotake Y, Yamamoto K, et al: Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer. Am J Clin Oncol. 31:11–21. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Greene FL, Page DL and Fleming ID: AJCC Cancer Staging Manual . 6th edition. Springer Verlag; New York: 2002, View Article : Google Scholar
12.	Bassi P, Ferrante GD, Piazza N, et al: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 161:1494–1497. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Madersbacher S, Hochreiter W, Burkhard F, et al: Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol. 21:690–696. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Shariat SF, Karakiewicz PI, Palapattu GS, et al: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Stockle M, Wellek S, Meyenburg W, et al: Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology. 48:868–875. 1996. View Article : Google Scholar
16.	Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE and Bajorin DF: Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 167:1295–1298. 2002. View Article : Google Scholar
17.	Stein JP, Cai J, Groshen S and Skinner DG: Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 170:35–41. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Herr HW: Superiority of ratio based lymph node staging for bladder cancer. J Urol. 169:943–945. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Cheng CW, Ng CF, Chan CK, Wong WS, Hui PE and Wong YF: A fourteen-year review of radical cystectomy for transitional cell carcinoma demonstrating the usefulness of the concept of lymph node density. Int Braz J Urol. 32:536–549. 2006.
20.	Kassouf W, Agarwal PK, Herr HW, et al: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 26:121–126. 2008. View Article : Google Scholar
21.	Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S and Studer UE: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 179:873–878. 2008. View Article : Google Scholar
22.	Konety BR, Joslyn SA and O’Donnell MA: Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 169:946–950. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Leissner J, Ghoneim MA, Abol-Enein H, et al: Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 171:139–144. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Koppie TM, Vickers AJ, Vora K, Dalbagni G and Bochner BH: Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 107:2368–2374. 2006. View Article : Google Scholar : PubMed/NCBI
25.	No authors listed: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists Lancet. 354:533–540. 1999.
26.	Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 349:859–866. 2003. View Article : Google Scholar : PubMed/NCBI
27.	Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 361:1927–1934. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Winquist E, Kirchner TS, Segal R, Chin J and Lukka H: Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 171:561–569. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Collins JM: Pharmacokinetic rationale for intraarterial therapy. Cancer Chemotherapy, Challenges for the Future. Kimura K: 4. Excepta Medica, Amsterdam; 1989
30.	Mitsuzane K, Kawabata M, Terada M, Nomura S, Sato M and Yamada R: Balloon-occluded arterial infusion as chemotherapy in bladder cancer-long-term results. Gan To Kagaku Ryoho. 17:1701–1704. 1990.(In Japanese).
31.	Talley RW, O’Bryan RM, Gutterman JU, Brownlee RW and McCredie KB: Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875) - phase I clinical study. Cancer Chemother Rep. 57:465–471. 1973.PubMed/NCBI
32.	Cvitkovic E, Spaulding J, Bethune V, Martin J and Whitmore WF: Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 39:1357–1361. 1977. View Article : Google Scholar : PubMed/NCBI
33.	Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M and Ghoneim MA: Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study - a single center experience. J Urol. 172:1818–1821. 2004. View Article : Google Scholar : PubMed/NCBI
34.	Vazina A, Dugi D, Shariat SF, Evans J, Link R and Lerner SP: Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 171:1830–1834. 2004. View Article : Google Scholar : PubMed/NCBI
35.	Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 8:1335–1339. 1979. View Article : Google Scholar : PubMed/NCBI
36.	Douple EB and Richmond RC: Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys. 5:1369–1372. 1979. View Article : Google Scholar : PubMed/NCBI
37.	Abbott DW, Freeman ML and Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst. 90:978–985. 1998. View Article : Google Scholar : PubMed/NCBI
38.	Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1391–1399. 1999.PubMed/NCBI